Open AccessManagement of a primary malignant melanoma of uterine cervix stage IVA patient with radical surgery and adjuvant oncolytic virus Rigvir ® therapy: A case report
Author(s) -
Pumpure Elizabete,
Dručka Eva,
Kigitoviča Dana,
Meškauskas Raimundas,
Isajevs Sergejs,
Nemiro Ineta,
Rasa Agnija,
Olmane Evija,
Zablocka Tatjana,
Alberts Pēteris,
Doniņa Simona
Publication year - 2020
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.2928
Subject(s) - medicine , adjuvant therapy , melanoma , stage (stratigraphy) , uterine cervix , adjuvant , radical surgery , tolerability , cervix , oncolytic virus , primary treatment , surgery , oncology , gynecology , cancer , carcinoma , chemotherapy , adverse effect , cancer research , paleontology , biology
Primary malignant melanoma of the uterine cervix is a rare disease with poor prognosis and high recurrence rate. We used Rigvir ® as adjuvant therapy for a stage IVA patient. Tolerability, overall and progression‐free survival are good.